read on light, the ultra-thin reading glasses launched at MIDO, the international eyewear fair in Milan
Zurich, Switzerland, 8 February 2024 – ‘read on’ , a Swiss start-up at the forefront of eyewear innovation, today announced the launch of its latest innovation: ‘read on light’. Ultra-thin, lightweight and highly flexible reading glasses, made of high-quality eyewear material (TR90). At only three millimeters, ‘read on light’ is one of the thinnest reading glasses on the market.
‘read on’ was founded by Sandra Kaufmann and Monika Fink, leaders in the international eyewear business, who established the fashionable Swiss eyewear brand 'Sol Sol Ito' (
· Phase 2 studies showed the TSS1-T vaccine to be safe and effective, offering potential preventative therapy for vulnerable groups and medical workers · Staphylococcal-induced TSS is a serious and life-threatening condition affecting patients with compromised immunity and premenopausal women · Results encouraging for the development of a toxoid-based, multi-component vaccine against sensitive and resistant Staphylococcus aureus infections, a significant threat to patients and financial burden for healthcare systems
Vienna, Austria, 9 January 2024 – The first vaccine to
OM Pharma, a global biopharmaceutical company headquartered in Switzerland, announced the appointment of Roch Ogier as Chief Executive Officer (CEO), effective January 1, 2024. He will succeed Josef Troxler, who will continue to share his expertise as Senior Advisor and Chairman of the Board of the Swiss Affiliate.Geneva, Switzerland, 6 December 2023 - OM Pharma’s Board of Directors has appointed Roch Ogier as Chief Executive Officer (CEO) with effect from January 1, 2024. Roch, currently Chief Operating Officer, brings a wealth of experience in the biotechnology field and across the
· Phase 2 studies showed the TSS1-T vaccine to be safe and effective, offering potential preventative therapy for vulnerable groups and medical workers
· Outcome is also a major step in the battle against MRSA infections
· Phase 3 trial preparation underway
· Staphylococcal-induced Toxic Shock Syndrome (TSS) is a serious and life-threatening condition affecting at risk patients, including those with compromised immunity and premenopausal women
· Methicillin-resistant Staphylococcus aureus (MRSA) is a constant threat to patients and a major financial burden for healthcare
Muttenz, Switzerland, 16 September 2021 – Opterion Health AG , a nephrology company focused on innovation in Peritoneal Dialysis (PD), today announced a significant strengthening of its management team, including the appointments of Daniel Lustenberger as Chief Financial Officer (CFO) and Peter Reinemer as Chief Technology Officer (CTO). Mylène Fleurant has been appointed Head of Quality and Ulrike Grimm Head of Project Management. Andreas Schmidt, whom Daniel Lustenberger succeeds as CFO, will continue to support Opterion Health as a partner.Opterion Health is
